Pfizer Inc. (PFE) Shares Sold by PDT Partners LLC

PDT Partners LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 82.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,200 shares of the biopharmaceutical company’s stock after selling 196,300 shares during the period. PDT Partners LLC’s holdings in Pfizer were worth $1,451,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the business. Sandhill Capital Partners LLC raised its position in shares of Pfizer by 3.2% during the second quarter. Sandhill Capital Partners LLC now owns 16,145 shares of the biopharmaceutical company’s stock worth $542,000 after purchasing an additional 504 shares during the period. Arete Wealth Advisors LLC raised its position in shares of Pfizer by 144.0% during the second quarter. Arete Wealth Advisors LLC now owns 33,528 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 19,787 shares during the period. Risk Paradigm Group LLC raised its position in shares of Pfizer by 867.5% during the second quarter. Risk Paradigm Group LLC now owns 27,166 shares of the biopharmaceutical company’s stock worth $913,000 after purchasing an additional 24,358 shares during the period. Summit Financial Wealth Advisors LLC raised its position in shares of Pfizer by 28.0% during the second quarter. Summit Financial Wealth Advisors LLC now owns 65,140 shares of the biopharmaceutical company’s stock worth $2,188,000 after purchasing an additional 14,247 shares during the period. Finally, Numeric Investors LLC raised its position in shares of Pfizer by 1,140.6% during the second quarter. Numeric Investors LLC now owns 204,700 shares of the biopharmaceutical company’s stock worth $6,876,000 after purchasing an additional 188,200 shares during the period. Hedge funds and other institutional investors own 69.89% of the company’s stock.

A number of brokerages have recently weighed in on PFE. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Friday. UBS set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price on the stock in a research report on Thursday, November 23rd. Finally, Jefferies Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.77.

Pfizer Inc. (NYSE PFE) traded up $0.24 during midday trading on Monday, reaching $35.74. The company had a trading volume of 14,901,100 shares, compared to its average volume of 19,939,289. The stock has a market cap of $213,035.67, a price-to-earnings ratio of 14.30, a P/E/G ratio of 2.52 and a beta of 1.01. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. research analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is currently 79.01%.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Insiders sold a total of 60,280 shares of company stock valued at $2,118,988 over the last three months. 0.06% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece was reported by Zolmax and is the property of of Zolmax. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://zolmax.com/investing/pfizer-inc-pfe-shares-sold-by-pdt-partners-llc/1838020.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Westlake Chemical  Earns Daily Coverage Optimism Score of 0.07
Westlake Chemical Earns Daily Coverage Optimism Score of 0.07
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Advanced Semiconductor Engnrng Stock Price
SVB Financial Group  Given News Impact Score of 0.43
SVB Financial Group Given News Impact Score of 0.43
CVR Partners LP  Given Consensus Recommendation of “Hold” by Brokerages
CVR Partners LP Given Consensus Recommendation of “Hold” by Brokerages
Prologis  Earns Daily Media Sentiment Rating of 0.06
Prologis Earns Daily Media Sentiment Rating of 0.06
KKR & Co. L.P.  Receiving Somewhat Favorable News Coverage, Report Shows
KKR & Co. L.P. Receiving Somewhat Favorable News Coverage, Report Shows


Leave a Reply

 
© 2006-2018 Zolmax.